Global Xerostomia Therapeutics Market to accrue $ 822.1 Mn by 2026

May 10, 2019


Global xerostomia therapeutics market size is expected to hit the USD 822.1 million mark by 2026 at a CAGR of 3.6% over the forecast period, according to the latest research available at Market Study Report LLC, report provides detailed segmentation of the xerostomia therapeutics market based on product type, application, end user and region.
 

Clinically known as xerostomia, dry mouth ailment pertains to decrease or absence of saliva in affected individuals. The condition, not generally considered as a disease, primarily occurs due to numerous clinical scenarios such as negative effects of radiation treatment on neck or head, or due to side effects of diverse medications. It may also be associated with waned functionality of salivary glands.
 

Credible reports claim that the condition is mainly occurs among senior citizens and is estimated to impact around 20% of the people across the globe. However, not particularly being an age-related issue, it is mainly attributed to drug side-effects.
 

Based on the findings of the report it can be claimed that the factors such as supportive compensation plans for xerostomia products and growing awareness and responsiveness about diseases associated with the condition would have a positive impact on the xerostomia therapeutics market growth over the forecast period. In addition, rising cases of xerostomia as well as relevant medical conditions like Sjogren’s disorder, Parkinson’s disease, high blood pressure, as well as diabetes mellitus will augment global market outlook.
 

The global xerostomia therapeutics market, being segmented by type, distribution-channel, and region, has garnered 625.3 million in 2018 and is anticipated to grow further at a CAGR of 3.6% between 2019 to 2026. Depending on the product landscape, the dentifrices market segment was likely the largest segment in 2018 due to its reduced pricing, increased adoptability, and availability. Moreover, the segment is closely followed by salivary stimulants product category which is estimated to register high growth rate during the forecast timeframe.
 

In terms of the distribution channel, the hospital pharmacy sector earned maximum market revenue in 2018, mainly due to ease of accessibility, availability of generic as well as branded medicines and reduced product cost.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/1868576/
 

Regionally speaking, North America is anticipated to be a prominent revenue ground followed by Europe over the estimated period. Rising awareness amongst people and initiatives taken by various companies and foundations is likely to push market growth in these regions. For instance, the report from Colgate-Palmolive Company estimates that over 25 million people in the U.S. suffer from dry mouth issue. Meanwhile, Sjogren Syndrome Foundation claims that over 4 million people in the U.S. suffer from Sjogrens disorder, which is one of the many syndromes that leads to dry mouth ailment.
 

Thus, to counter this issue, the foundation is actively running awareness programs in the U.S. for people suffering from this condition and to educate the public in general. Such initiatives have extensively pushed the overall market growth in the U.S.
 

The report cites that in the Asia Pacific region the market is expected to witness higher growth rate owing to advancements in the medical sector and increased spending on healthcare in emerging nations like China and India.
 

Additionally, as numerous foundations are creating awareness among people, several major pharmaceutical companies are actively initiating acquisitions and joint ventures with emerging firms to increase their product portfolio and endorse awareness among the people, further pushing the overall market size.
 

The leading companies profiled in the study include Church & Dwight Co., Inc, Colgate-Palmolive Company, EUSA Pharma, Forward Science, GlaxoSmithKline plc, Mission Pharmacal Company, OraHealth Inc., Eisai Inc., Parnell Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, Saliwell Ltd., OraPharma, Inc, and Dentaid.